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Case series of vaccine associated varicella zoster virus
infection in immune compromised patients.
Vaccination with attenuated varicella zoster virus (VZV)
can lead to infectious complications in immunodeﬁcient
patients. Here we report two immunocompromised patients
who developed initial or reactivated vaccine strain varicella,
leading to unique vesicular rashes involving the vaccinated
limbs, without becoming wide-spread or remaining limited
to a single dermatome.
Case 1- A 5 year old female presented with fever, jaun-
dice, epistaxis and petechiae which began 2 weeks after
receiving a second Varivax vaccination. Diagnostic testing
revealed pancytopenia and hepatitis with a peak ALT of 1712
unit/L. A liver biopsy showed diffuse portal and lobular
hepatocellular inﬂammation with prominent lymphohistio-
cytic inﬁltrate. A bone marrow aspirate and biopsy revealed
hypocellularity and hemophagocytosis. She soon developed
vesicles on her right arm and shoulder in a non-dermatomal
pattern (Figure 1). The lesions remained localized to the
entire right upper extremity, which was the site of the earlier
Varivax vaccination. A vesicle was unroofed and the ﬂuid
tested positive for VZV by PCR. Further analysis revealed the
virus to be vaccine strain varicella. She was treated with
intravenous acyclovir and the lesions crusted over 21 days
from presentation.
Case 2- A 17 month old female with Hurler Syndrome, on
day + 6 after receiving an unrelated 7/8 Human Leukocyte
Antigen matched cord blood transplant, developed a vesic-
ular rash on her right thigh ,which was the site for Varivax
vaccination 4 months prior to transplant. A lesion was
unroofed and the ﬂuid revealed VZV by PCR. Subsequent
analysis revealed the virus to be vaccine strain varicella. She
was started on treatment with intravenous acyclovir and
intravenous immunoglobulin and her lesions crusted over
within 2 weeks.
These two cases highlight unusual presentations of
vaccine strain varicella in immunocompromised patients.
Vaccine strain varicella can cause a vesicular rash in a non-
classical distribution. It is also notable that vaccine strain
virus can trigger hemophagocytic lymphohistiocytosis in
immune deﬁcient patients.Table 1
Disease (age in years) Stem cell donor/source,
HLA match
Day of WBC
engraftment
Acute/C
WAS (2) URD/marrow, 10/10 +26 Stage I
Hunter Syndrome (5) URD/marrow, 10/10 +28 None
Hurler Syndrome (1) URD/marrow, 10/10 +27 Stage 1
Sickle beta-
thalassemia (24)
mMRD/marrow8/10 +17 None
Sickle Cell (11) mMRD/marrow8/10 +16 Stage 1
gut/no
Sickle Cell (8) URD/marrow, 10/10 +18 Stage1
dateFigure 1. Entire vaccinated limb involved in a non dermatomal pattern
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The genetic lymphohematopoietic diseases have been
effectively treated and cured by performing allogeneic HCT
from a histocompatible sibling donor following a standard
conditioning regimenwith busulfan (BU), cyclophosphamide
(CY), and antithymocyte globulin, and recently with reduced
intensity conditioning (RIC) regimens. With the use of either
conventional conditioning or RIC, the biggest limitation of
these approaches is the lack of a fully HLA-matched sibling
donor. Higher risks of graft rejection and graft-versus-host
disease (GVHD) with the use of non-matched sibling donors
e including unrelated donors (URD) or mismatched related
donors (mMRD) makes these transplants high risk with high
rates of treatment related mortality (TRM). We report
preliminary results (Table 1 below) on six patients with
genetic lymphohematological disorders lacking fully
matched sibling donors whowere transplanted using a novelhronic GvHD Viral infections Outcome (length of f/up)
II skin/skin None Alive (6 yrs), off
immunosuppression (IS)
CMV Alive (5 yrs), off IS
skin/none None Alive (3 yrs), off IS
CMV Alive (3 yrs), off IS
skin, stage 1
ne
CMV, HHV-6, Adeno,
and BK
Alive (11 mo), off IS
skin/none to HHV-6 and Adeno Alive (110 days), on IS
